

Humber Area Prescribing Committee

Date / Time	3 rd May 2023 13:00-15:00
Venue	MS Teams
Chair	Dr Sergio Raise
Notes / Action Points	Luke Storr – Senior Pharmacy Technician, HUTH
Quorate: Yes / No	No – JM to send papers to (items ratified after meeting)

Attendance	Dr Sergio Raise, ERY CCG GP Prescribing Lead (SR) Jane Morgan, Principal Pharmacist - Formulary, Interface and Medicines Commissioning, HUTH (JM) Luke Storr – Senior Pharmacy Technician, HUTH (LS) Kevin McCorry, Medicines Optimisation Pharmacist, NECS (KMc) Dr Rolan Schreiber, Professional Secretary LMC (RSc) Emma Baggaley, Assistant Director Medicines Management (Superintendent Pharmacist), CHCP (EB) Andrew Karvot – Advanced Clinical and Northern Lincolnshire Interface Pharmacist, NLAG (AK) Prof A Morice, Professor of Respiratory Medicine HUTH- (AM) Naida Rafiq- Medicines Optimisation Pharmacist- NECS (NR) Daniel Newsome- Principal Pharmacist RDTC (DN) Simon Priestley- Chief Pharmacist, NLAG (SP) Joanne Goode – Chief Pharmacist – HUTH (JG) Weeliat Chong, Chief Pharmacist, Humber Teaching NHS Foundation Trust (WC) Oliver Fillingham - Locality Pharmacist, NECS (OF)
-------------------	---

Apologies	Laura Bulmer, Pharmacy Technician Project Manager, NECS (LB) Rachel Staniforth, Medicines Optimisation Pharmacist, NECS (RS) Narayana Pothina- Consultant in adult medicine, NLAG (NP) Dr Anupam Sinha- NEL GP Prescribing Lead (AS) Caroline Hayward- Professional Development Pharmacist, Humber Local Pharmaceutical Committee (CH) Ester Sanni- Principle Pharmacist, Humber Teaching NHS Foundation Trust (ES)
------------------	--

Agenda Number	Item	Discussion	Action	Lead	Due Date
2023.05.01	Apologies	Noted above			
2023.05.02	Declarations of interest	None			
2023.05.03	Minutes of previous meeting	Accepted as true record			
2023.05.04	Action Tracker	<p>Prescription requests in primary care –action transferred from NLAPC to Humber APC To produce joint document detailing supply details from secondary to primary care for all providers within Humber region To add links to relevant HUTH and NLAG guidance to website for information for primary care (discharge policies)</p> <p>Ratification of guidelines and SCFs Add type 2 diabetes guidelines as recommendation for discussion at IMOC (action complete) NEW actions To feedback IMOC recommendation to clinicians To feedback to APC when meeting between all services occurred December update – going around internal governances in trusts (HUTH/NLAG/Y&SFT/HDH) March update – still awaiting outcome from relevant governances, JM to discuss with Matthew Heppel</p> <p>Action tracker HERPC – Hydroxychloroquine SCF JM to prepare hydroxychloroquine SCF</p> <p>Action tracker NLAPC – Triptorelin JM/AK to share HERPC guideline with Mr Rogers for transfer into a joint document December update still ongoing Discussion regard Mr Rogers and updating the costing</p>	<p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p> <p>Document to be sent to Guideline group- Remove from tracker</p>	<p>JM</p> <p>JM</p> <p>JM</p> <p>JM/AK</p>	<p>6/23</p> <p>8/23</p> <p>6/23</p> <p>3/23</p>

		<p>Outstanding actions from NLAPC Funding for SCFs – mycophenolate, modafinil and riluzole (joint SCFs) December update: JM provided RS with patient numbers for mycophenolate, modafinil and riluzole Feb update- Modafinil live in NEL Riluzole live in NEL March update: SCFs uploaded onto Humber APC and linked into formulary. Awaiting NL – RS to update</p> <p>Outstanding actions from NLAPC Funding for SCF – Azathioprine/6MP (NEL/N) AK to provide RS information on number of patients in NEL/NL Feb update Azathioprine live in NEL March update: SCF uploaded onto website, awaiting NL – RS to update</p> <p>Outstanding actions from NLAPC ADHD shared care (NL) – Awaiting confirmation of funding. Going to next mental health primary/secondary care interface meeting. RS to update when feedback received March update: Formulary updated ready for go live.</p> <p>Outstanding actions from NLAPC Atomoxetine liquid – SCF ADHD shared care NL awaiting funding (as per other action). NEL within current SCF. February update: planned for March go line for NL</p> <p>Outstanding actions from HERPC Renal repatriation: December update – JM to meet with renal Dec update – JM offered dates of meeting but no correspondence March update – Updating business case.</p> <p>Ratification of joint formulary To upload chapter 13 on netformulary and remove HERPC chapter March update – still ongoing</p> <p>Traffic light status To update formulary and red list</p> <p>Ratification of guidelines and SCFs JM to complete updates requested on guidance and upload onto website, remove relevant HERPC guidance and note on</p>	<p>Riluzole- Approved in NL. JM to update website with change to riluzole Others ongoing</p> <p>Azathioprine approved in NL</p> <p>Ongoing/On agenda as AOB</p> <p>Ongoing- on agenda</p> <p>Ongoing</p> <p>Ongoing</p> <p>Action complete</p> <p>Action complete</p>	<p>JM/RS</p> <p>AK</p> <p>RS</p> <p>RS</p> <p>JM</p> <p>JM/AK/LS</p> <p>AK/LS</p> <p>JM</p>	<p>6/23</p> <p>6/23</p> <p>2/23</p> <p>2/23</p> <p>12/22</p> <p>6/23</p> <p>4/23</p> <p>4/23</p>
--	--	--	---	---	--

		HERPC website which guidance has moved to Humber APC guidance RTDC updates To update formulary with TAs which were approved	Action complete	JM/AK	4/23
2023.05.05	Outstanding actions from HERPC	<ul style="list-style-type: none"> Correspondence Received Rheumatology to prepare pathway with rituximab without MTX August update – JM to contact Dr Ogumbambi for timeline October update – JM to contact Dr Ogumbambi again November update – Arranging meeting to discuss guidance and timeframe December update – Meeting booked February update – Documents sent to Dr Ogumbambi – March update – JM chased Dr Ogumbambi as received NLAG documents April update – JM to chase Dr Ogumbambi again Feedback From Commissioning Groups KMc and JM to work with CCG to approve MS guideline August update – JM to contact Gary Hepworth September update – JM updated document and to send to Gary Hepworth October update – JM sent to Gary Hepworth November update – Been circulated awaiting comments. December update – JM to update and send to guideline group for discussion February update – to add to next guideline group for discussion March update – to add to next guideline group Discussed at guideline group for next APC agenda April update – for next APC agenda Hydroxychloroquine SCF JM to discuss ophthalmology checks with rheumatology New action:JM to add Harrogate pathway to agenda when published. New Action: JM to meet with business manager in ophthalmology to discuss drafting HUTH pathway and work towards commissioning. September 2022 update – HUTH D&T are escalating internally via their escalation process. To prepare SCG (action for HAPC) 	Ongoing	JM	9/22
			Ongoing- Add to next HAPC agenda	JM/KMc	12/22
			Ongoing- Not discussed at PE&CE- Discuss at HUTH D&T	JM	1/23

		<p>October 2022 – HUTH D&TC haven't had reply from their escalation process (JM chasing)</p> <p>November 2022 – HUTH D&TC haven't had reply from their escalation process</p> <p>December 2022 – HUTH meeting later this month.</p> <p>February 2023 – To check PE&CE minutes</p> <p>March 2023 – To discuss PE&CE response at next D&TC</p> <p>April 2023 – To discuss at next HUTH D&TC</p> <ul style="list-style-type: none"> • Prescribing guidelines – Dienogest pathway <p>JM to confirm prescribing arrangements with specialist team</p> <p>October update: JM contacted Mrs Allen who is service lead, noted not stocked in HUTH pharmacy, thus stock arranged in pharmacy. No response from e-mail to consultant but specialist nurse responded.</p> <p>November update – JM to check formularies and EMIS dispensing system.</p> <p>December update – JM to chase consultant</p> <p>February update – JM met consultant and going to update pathway</p> <p>March update –JM to update pathway</p>	Ongoing- add to next guideline agenda	JM	3/22
2023.05.06	Traffic Light Status	<p>Morphine sulphate orodispersible tablets (Actimorph®)- Proposed as RED- Discussion ending with approved as GREEN as per other morphine sulphate preparations</p> <p>Aprotinin- Approved as RED</p> <p>Tezepelumab- Approved as RED</p> <p>Buspirone- Approved as AMBER 1</p> <p>Tranexamic acid oral preparations- Approved as GREEN</p> <p>Dapagliflozin / Empagliflozin for heart failure indication- Approved as AMBER 1 both first line</p>	Update formulary/red list	LS/AK	4/23
2023.05.07	Feedback from Integrated Medicines Optimisation Committee	<ul style="list-style-type: none"> • Discussion on diabetes pathway and costings • Continued discussions on dexcom and pathway policy which needs ICB approval • KMc added potentially using dexcom instead of freestyle libra in same commissioning statement • Private prescribing guidance 	Noted		
2023.05.08	Work plans	<ol style="list-style-type: none"> a) Joint formulary alignment b) Shared care frameworks c) Guidelines 	Ongoing for information only		
2023.05.09	Ratification of guidelines and SCFs	<ol style="list-style-type: none"> a) MS guideline- Updated flow chart b) ADHD 	<ol style="list-style-type: none"> a) Approved b) Approved 	JM	4/23

2023.05.10	Ratification of joint formulary	Chapter 1	Accepted		
2023.05.11	RTDC updates	<ul style="list-style-type: none"> March 23- to update formulary 	Update formulary/red list	JM/LS/AK	4/23
2023.05.12	Blueteq Forms	<ul style="list-style-type: none"> Discussion on use of Blueteq for UC in NLaG Blueteq deviation and costing to be added to Action tracker 	Add to Tracker		
2023.05.13	Minutes from subcommittees	<ol style="list-style-type: none"> Joint formulary subcommittee (Feb 23) Guideline subcommittee (Nil) 	Attached for info only		
2023.05.14	Additional minutes for information	<ol style="list-style-type: none"> HUTH D&TC (Feb 23) HFT DTG (Jan 23) NLAG M&T (Nil) NYY APC (March 23) 	Attached for info only		
2023.05.15	Correspondence received	Nil this Month			
2023.05.16	AOB	KMc asked JM if anti-psychotics meeting has been arranged	Ongoing		
2023.05.17	Date of next meeting	7 th June 13.00 – 15.00 Teams			